Préime DermaCeuticals

Professional · Injectable Solutions · GCC Exclusive

Préime
DermaCeuticals

14 solutions · Exosome · PDRN · Brightening · Lifting · Scalp

PRÉIME · DermaCeuticals

The Science of
Injectable Aesthetics

Préime DermaCeuticals is a professional injectable range engineered for clinicians who demand precision and results. Each of the 14 solutions is formulated with pharmaceutical-grade actives — from PDRN and exosome technology to tranexamic acid, phosphatidylcholine and stabilised retinol.

Trusted by aesthetic clinics across the GCC. Distributed exclusively in Qatar, UAE, Bahrain and the wider region by GMEDCO.

14

Solutions

4

Categories

GCC

Exclusive

Préime DermaCeuticals — Pure Bright, Pure, PDRN Booster

Injectable Solutions — All 14

PDRN Booster
Préime DermaCeuticals · Exosome
Nucleotide Rejuvenating Solution

PDRN Booster

Cellular Renewal at the Dermal Level.

Polydeoxyribonucleotides (PDRN) are DNA-derived fragments that activate A2A purinergic receptors to accelerate tissue repair. PDRN Booster harnesses this mechanism to visibly reduce wrinkles, improve skin texture and restore a rejuvenated appearance over a clinical course.

Category

Nucleotide Solution

Indication

Skin Rejuvenation

Protocol

4–6 sessions

Areas

Face · Neck

Key Composition

Polydeoxyribonucleotides (PDRN), Nucleotide Complex

Treatment Areas

Face · Neck · Décolletage

Key Benefits

PDRN Booster

01

A2A Receptor Activation

PDRN triggers purinergic receptors that drive tissue regeneration at the cellular level.

02

Wrinkle Reduction

Enhances dermal collagen synthesis for visible improvement in fine lines and wrinkles.

03

Texture Refinement

Targets skin imperfections and uneven texture for a visibly smoother complexion.

04

Sustained Rejuvenation

Progressive improvement compounds between sessions for lasting regenerative results.

PDRN Booster

Préime DermaCeuticals

PDRN Booster

Navigate Range

Exclusive GCC Distribution

Request a Demo
or Quotation

Available exclusively through GMEDCO for clinics in Qatar, UAE, Bahrain and across the GCC.